Alflutinib - Allist Pharmaceuticals

Drug Profile

Alflutinib - Allist Pharmaceuticals

Alternative Names: Alflutinib mesylate; AST-2818

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allist Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 08 Mar 2018 Allist Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in April 2018 (NCT03452592)
  • 02 May 2017 Allist Pharmaceuticals plans a clinical trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, In operable/Unresectable, Recurrent, Second-line therapy or greater) (NCT03127449)
  • 01 Dec 2016 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Recurrent) in China (PO) (NCT02973763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top